Generics Cos. Rip AstraZeneca's Crestor IP In Fed. Circ.
By Christopher Norton ( October 5, 2011, 4:27 PM EDT) -- A slew of generic-drug companies defending against AstraZeneca PLC's multidistrict infringement litigation over Crestor told the Federal Circuit on Wednesday that a patent for the cholesterol drug is invalid because the patentees omitted prior art references in the application....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.